ClinicalTrials.gg
CompletedNCT04547543VISIOSASUpdated Oct 13, 2026

Follow-up of Apneic Patients by Visio-consultation

An interventional study of Videoconsultation in Obstructive Sleep Apnea, sponsored by University Hospital, Grenoble. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University Hospital, Grenoble · Not applicable, Interventional, and Health services research

How we know

Updated Oct 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble — 6 open to participants now, 6 under way, none of them phase 3. Sleep Apnea, Obstructive · University Hospital, Grenoble.

Enrollment
4th of 32
250 · median 54
Started
2020
with 5 others
No phase
25 of 48
4 open now
Registered
40th of 48
by date

Among the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, this one is the 4th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2020, is one of 25 with no phase, and was the 40th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Sleep Apnea, Obstructive by University Hospital, Grenoble, or all of them as a file.
02

Study summary

Prospective multicenter open-label randomized clinical trial comparing videoconsultation to a face-to-face consultation during the follow-up of apneic patients treated by continuous positive pressure (CPAP) .

Read the detailed description

The annual management of Obstructive Sleep Apnea (OSA) patients treated by continuous positive air pressure (CPAP) aims to maintain an optimal level of care while offering to the patients a combined management of their pathology. This management aims to reduce the risk of cardio-metabolic pathologies.

However, the high prevalence of OSA in the general population reduces the ability to explore undiagnosed patients. The contribution of videoconsultation is now available and allows the management of OSA patients treated by CPAP.

The objective of this study is to compare the videoconsultation to a face-to-face consultation during the follow-up of apneic patients treated by continuous positive pressure (CPAP) .

The results of this study could provide very important new data on the impact of videoconsultation on the monitoring a chronic respiratory pathology such as sleep apnea.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Telemedicine
  • Medical follow-up
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Apneic patient treated with CPAP for more than 12 months and having an annual scheduled follow-up visit.
  • Adult patient who can give an .
  • Patient with access to a media (Smartphone, tablet or computer) and an Internet connection at home.

Exclusion criteria

Exclusion Criteria:

  • Patient unable to use or understand the digital system.
  • Patient under guardianship or deprived of liberty
  • Pregnant woman
  • Patient in a period of exclusion from another clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (actual)

Study arms

  • Other
    Video consultation

    Patients in this group will have a continuous positive pressure follow-up visit by videoconsultation

    Other: Videoconsultation

  • No intervention
    Face-to-face consultation

    Patients in this group will have a continuous positive pressure follow-up visit by face-to-face consultation

Interventions

  • OtherVideoconsultation

    Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status

06

What researchers measure

Primary outcomes

  1. Therapeutic adherence to CPAP

    Non inferiority of visioconsultation compared to face-to-face consultation in terms of therapeutic adherence to CPAP evaluated by the difference in compliance 3 months before and 3 months after the consultation

    Time frame: 3 months after consultation

  2. Consultation cost

    Non inferiority of visioconsultation compared to face-to-face consultation in terms of consultation cost evaluated by the difference in cost between the 2 types of consultation

    Time frame: 3 months after consultation

  3. Patient satisfaction: questionnaire

    Non inferiority of visioconsultation compared to face-to-face consultation in terms of patient satisfaction evaluated by the VSQ-VF questionnaire

    Time frame: 3 months after consultation

Secondary outcomes

  1. Sleepiness related to CPAP

    Epworth Sleepiness Scale

    Time frame: 3 and 12 after consultation

  2. Tiredness related to CPAP

    Pichot's fatigue scale

    Time frame: 3 and 12 months after consultation

  3. Evaluate the quality of CPAP treatment (Residual AHI)

    Evaluate the quality of CPAP treatment by the residual Apnea-Hypopnea Index(AHI) (event/hour)

    Time frame: 3 and 12 months after consultation

  4. Evaluate the quality of CPAP treatment (adverse events)

    Evaluate the quality of CPAP treatment by the adverse event reporting

    Time frame: 3 and 12 months after consultation

  5. Evaluate the quality of CPAP treatment (mask leaks level)

    Evaluate the quality of CPAP treatment by the CPAP mask leaks level (litre/min)

    Time frame: 3 and 12 months after consultation

  6. Evaluate the quality of CPAP treatment (visits by the health care provider): number of visits by the health care provider and the reasons for these visits

    Evaluate the quality of CPAP treatment by collecting the number of visits by the health care provider and the reasons for these visits

    Time frame: 3 and 12 months after consultation

  7. Assess the risk factors associated with OSA in patients treated with CPAP (weight)

    Body weight (kg)

    Time frame: 12 months after consultation

  8. Assess the risk factors associated with OSA in patients treated with CPAP (level of physical activity)

    Evaluation of the level of physical activity by actimetry

    Time frame: 12 months after consultation

  9. Assess the risk factors associated with OSA in patients treated with CPAP (blood pressure)

    Blood pressure by blood pressure monitoring at home

    Time frame: 12 months after consultation

07

Study locations

1 site
  • CHU Grenoble-Alpes
    Grenoble, 38043, France
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Sep 2025, 60 months.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's 60 months is above that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Mar 2026 → Sep 2025 and completion Mar 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2020
First posted
Sep 14, 2020
StartActual
Sep 8, 2020
Primary completionActual
Sep 30, 2025was Mar 2026
CompletionActual
Aug 5, 2026was Mar 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Primary completion
Mar 2026→Sep 30, 2025 (actual)
Oct 13, 2026
Study completion
Mar 2026→Aug 5, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    Primary completion Mar 2026→Sep 30, 2025 (now actual)
    Study completion Mar 2026→Aug 5, 2026 (now actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04547543
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Sep 8, 2020
Primary completion
Sep 30, 2025
Completion
Aug 5, 2026
Last update
Oct 13, 2026

Study contacts

Renaud TAMISIER, Pr
principal investigator · University Hospital, Grenoble

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion